CAGR of 4.4% forecast for global HER2-positive breast cancer market

The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer market across the eight major countries of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to rise from $6.4 billion in 2015 to $9.89 billion in 2025, representing a compound annual growth rate (CAGR) of 4.4%.

According to research and consulting firm GlobalData’s latest report, the adjuvant and neoadjuvant settings remain the greatest contributors to sales, with combined forecasts expected to reach $4.96 billion in 2025, representing 50% of the total HER2-positive market. This surge in market size will be driven primarily by the anticipated launch of Swiss pharma giant Roche’s (ROG: SIX) Perjeta (pertuzumab) in the adjuvant setting, which will increase treatment duration compared to the neoadjuvant setting and protect Herceptin (trastuzumab) sales from biosimilar erosion in established markets.

Max Bourgognon, healthcare analyst for GlobalData, explains: “The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to position their products in these settings. However, many agents have failed to demonstrate clinical benefit over the currently cemented standard of care, meaning the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 monoclonal antibodies (MAbs), hence constituting the most lucrative opportunity for biosimilar developments.”